RecruitingNot Applicable

AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients.

Belgium210 participantsStarted 2026-02-15

Plain-language summary

This research forms part of a continuous quality improvement initiative. It aims to assess patient compliance of oral therapies by artificial intelligence. It could overcome the limitations of current practices and enhance the responsiveness and accuracy of clinical interventions.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients aged 18 and over who are treated in the Haematology Department at the Grand Hôpital de Charleroi from November 2025 onwards * Treated for a lymphoma, Non Hodgkin * Capable of giving informed consent Exclusion Criteria: * All other patients who did not meet the eligibility criteria

What they're measuring

ROC-AUC

Timeframe: 2027

Trial details

NCT IDNCT07546188

SponsorGrand Hôpital de Charleroi

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12-31

Contact for this trial

Marie Detrait, MD, PhD

0032 60 11 20 08 marie.detrait@ghdc.be

View on ClinicalTrials.gov More Lymphoma, Non-Hodgkin trials